ERIC WILKINSON: Open Payments
NPI 1396442232 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,333 in 183 payments from 14 companies in 2025. Trend: 2023 $1,275 · 2024 $1,677 · 2025 $3,333
Food & beverage: $3,333
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 22 | $740 |
| E.R. Squibb & Sons, L.L.C. | 26 | $411 |
| Alkermes, Inc. | 18 | $373 |
| Teva Pharmaceuticals USA, Inc. | 24 | $372 |
| ABBVIE INC. | 23 | $285 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $253 |
| Otsuka America Pharmaceutical, Inc. | 17 | $192 |
| Janssen Pharmaceuticals, Inc | 9 | $178 |
| Lundbeck LLC | 9 | $150 |
| Axsome Therapeutics, Inc. | 6 | $115 |
Products named: INGREZZA, COBENFY, ARISTADA, AUSTEDO XR, VRAYLAR, REXULTI, CAPLYTA, SPRAVATO.
Industry payments across FL — which companies pay providers there.
